Rechallenge in GIST progressing to imatinib, sunitinib and regorafenib: An Italian survey

被引：0
|
作者：
Vincenzi, B. [1 ]
Nannini, M. [2 ]
Grignani, G. [3 ]
Fumagalli, E. [4 ]
Gasperoni, S. [5 ]
D'Ambrosio, L. [1 ]
Badalamenti, G. [6 ]
Tos, A. P. Dei [7 ]
Incorvaia, L. [6 ]
Casali, P. [4 ]
Santini, D. [1 ]
Tonini, G. [1 ]
Stellato, M. [1 ]
Catania, G. [1 ]
Ceruso, M. Spalato [1 ]
Pantaleo, M. A. [8 ]
机构：
[1] Univ Campus Biomed Roma, Rome, Italy
[2] Univ Bologna, Bologna, Italy
[3] IRCCS, Candiolo Canc Inst FPO, Div Med Oncol, Sarcoma Unit, Turin, Italy
[4] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[5] Azienda Osped Univ Careggi, Florence, Italy
[6] Univ Palermo, Sect Med Oncol, Dept Surg Oncol & Oral Sci, Palermo, Italy
[7] Azienda ULSS 9 Treviso, Treviso, Italy
[8] Univ Bologna, Bologna, Italy
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
F1
引用
收藏
页码：60 / 60
页数：1
相关论文
共 50 条
  • [1] Rechallenge in advanced GIST progressing to imatinib, sunitinib and regorafenib: An Italian survey.
    Vincenzi, Bruno
    Nannini, Margherita
    Grignani, Giovanni
    Fumagalli, Elena
    Gasperoni, Silvia
    D'Ambrosio, Lorenzo
    Badalamenti, Giuseppe
    Dei Tos, Angelo Paolo
    Incorvaia, Lorena
    Casali, Paolo G.
    Santini, Daniele
    Tonini, Giuseppe
    Stellato, Marco
    Catania, Giovanna
    Ceruso, Mariella Spalato
    Pantaleo, Maria A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] REGORAFENIB IS EFFECTIVE AGAINST IMATINIB- AND SUNITINIB-RESISTANT GIST
    不详
    [J]. CANCER DISCOVERY, 2012, 2 (07) : 577 - 577
  • [3] Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib
    Vincenzi, Bruno
    Nannini, Margherita
    Badalamenti, Giuseppe
    Grignani, Giovanni
    Fumagalli, Elena
    Gasperoni, Silvia
    D'Ambrosio, Lorenzo
    Incorvaia, Lorena
    Stellato, Marco
    Ceruso, Mariella Spalato
    Napolitano, Andrea
    Valeri, Sergio
    Santini, Daniele
    Tonini, Giuseppe
    Casali, Paolo Giovanni
    Dei Tos, Angelo Paolo
    Pantaleo, Maria Abbondanza
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [4] ESMO: Regorafenib Improved PFS for GIST in Post-Imatinib/Sunitinib Setting
    不详
    [J]. ONCOLOGY-NEW YORK, 2012, 26 (11): : 1072 - 1072
  • [5] Rechallenge with imatinib in GIST: is more always RIGHT?
    Urban, Damien
    Lewin, Jeremy
    Collins, Ian M.
    Mooi, Jennifer
    Jefford, Michael
    [J]. LANCET ONCOLOGY, 2014, 15 (01): : E2 - E3
  • [6] Sunitinib for imatinib-resistant GIST
    Joensuu, Heikki
    [J]. LANCET, 2006, 368 (9544): : 1303 - 1304
  • [7] Regorafenib: A Guide to Its Use in Advanced Gastrointestinal Stromal Tumor (GIST) After Failure of Imatinib and Sunitinib
    Lyseng-Williamson, Katherine A.
    [J]. BIODRUGS, 2013, 27 (05) : 525 - 531
  • [8] Regorafenib: A Guide to Its Use in Advanced Gastrointestinal Stromal Tumor (GIST) After Failure of Imatinib and Sunitinib
    Katherine A. Lyseng-Williamson
    [J]. BioDrugs, 2013, 27 : 525 - 531
  • [9] Improved outcome with multimodal treatment and imatinib rechallenge in advanced GIST
    Gasparotto, Daniela
    Miolo, Gianmaria
    Torrisi, Elena
    Canzonieri, Vincenzo
    Bertola, Giulio
    Libra, Massimo
    Marzotto, Alessandra
    Maestro, Roberta
    Buonadonna, Angela
    [J]. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2014, 29 (05) : 639 - 640
  • [10] Improved outcome with multimodal treatment and imatinib rechallenge in advanced GIST
    Daniela Gasparotto
    Gianmaria Miolo
    Elena Torrisi
    Vincenzo Canzonieri
    Giulio Bertola
    Massimo Libra
    Alessandra Marzotto
    Roberta Maestro
    Angela Buonadonna
    [J]. International Journal of Colorectal Disease, 2014, 29 : 639 - 640
12345